Characteristics of responders and nonresponders to rituximab
Measure . | Responders, median (range) . | Nonresponders, median (range) . | P* . |
|---|---|---|---|
| No. | 11 | 25 | |
| Age at enrollment, y | 12.8 (7.5-17.4) | 11.0 (2.6-18.3) | .23 |
| ITP duration, y | 4.6 (0.6-11.6) | 3.0 (0.6-12.1) | .56 |
| Prior treatments | 4.0 (3.0-8.0) | 4.0 (2.0-7.0) | .54 |
| Initial platelet count, 1000/mm3 | 9.0 (1.0-27.0) | 10.0 (5.0-26.0) | .56 |
| Change in IgM level, mg/dL | −26.0 (−150.1-+23.6) | −27.6 (−99.1-+5.9) | 83 |
Measure . | Responders, median (range) . | Nonresponders, median (range) . | P* . |
|---|---|---|---|
| No. | 11 | 25 | |
| Age at enrollment, y | 12.8 (7.5-17.4) | 11.0 (2.6-18.3) | .23 |
| ITP duration, y | 4.6 (0.6-11.6) | 3.0 (0.6-12.1) | .56 |
| Prior treatments | 4.0 (3.0-8.0) | 4.0 (2.0-7.0) | .54 |
| Initial platelet count, 1000/mm3 | 9.0 (1.0-27.0) | 10.0 (5.0-26.0) | .56 |
| Change in IgM level, mg/dL | −26.0 (−150.1-+23.6) | −27.6 (−99.1-+5.9) | 83 |
Testing equal distribution in responders and nonresponders by exact Wilcoxon rank-sum test.